Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features

Version 1 : Received: 17 February 2024 / Approved: 18 February 2024 / Online: 19 February 2024 (10:25:15 CET)

A peer-reviewed article of this Preprint also exists.

Satake, D.; Natsumeda, M.; Satomi, K.; Tada, M.; Sato, T.; Okubo, N.; Kawabe, K.; Takahashi, H.; Tsukamoto, Y.; Okada, M.; Sano, M.; Iwabuchi, H.; Shibata, N.; Imamura, M.; Imai, C.; Takami, H.; Ichimura, K.; Nishikawa, R.; Umezu, H.; Kakita, A.; Oishi, M. Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Curr. Oncol. 2024, 31, 1831-1838. Satake, D.; Natsumeda, M.; Satomi, K.; Tada, M.; Sato, T.; Okubo, N.; Kawabe, K.; Takahashi, H.; Tsukamoto, Y.; Okada, M.; Sano, M.; Iwabuchi, H.; Shibata, N.; Imamura, M.; Imai, C.; Takami, H.; Ichimura, K.; Nishikawa, R.; Umezu, H.; Kakita, A.; Oishi, M. Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Curr. Oncol. 2024, 31, 1831-1838.

Abstract

Molecular analysis of growing teratoma syndrome has not been extensively studied. Here, we report a 14-year-old boy with a growing mass during treatment for a mixed germ cell tumor of the pineal region. Tumor markers were negative; thus, growing teratoma syndrome was suspected. A radical resection via the occipital transtentorial approach was performed, and histopathological examination revealed a teratoma with malignant features. Methylation classifier analysis confirmed the diagnosis of teratoma, and DMRT1 loss and 12p gain were identified by copy number variation analysis, potentially elucidating the cause of growth and malignant transformation of the teratoma. The patient remains in remission after intense chemoradiation treatment as a high-risk germ cell tumor.

Keywords

growing teratoma syndrome; multimodal treatment; methylation classifier; copy number variation analysis

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.